Nanoscope Therapeutics Leadership to Present at Advanced Therapies USA 2026
Nanoscope Therapeutics, Inc. has announced that its executive leadership team will participate in the Advanced Therapies USA 2026 conference held in Boston from November 4–5, 2026. The company's representatives will engage in several sessions covering gene therapy landscapes, neurodegenerative disease treatments, and market access strategies for rare diseases. The presentations are expected to highlight the scientific and commercial pathways for MOGENRY® (sonpiretigene isteparvovec; MCO-010), a mutation-agnostic optogenetic gene therapy. This product is currently under regulatory review by both the FDA and the PMDA, making these discussions critical for stakeholders monitoring the company's progress toward commercialization.
Tickers: $MNTS
Topics: Biotechnology Cell and Gene Therapy Market Access Neurodegenerative Conditions